精华制药
(002349)
| 流通市值：62.37亿 | | | 总市值：63.66亿 |
| 流通股本：8.14亿 | | | 总股本：8.31亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 754,772,245.25 | 379,763,838 | 1,459,957,149.65 | 1,092,285,389.95 |
| 营业总成本 | 563,082,590.66 | 283,381,216.65 | 1,161,319,446.31 | 853,284,673.64 |
| 其他经营收益 | | | | |
| 营业利润 | 191,771,169.98 | 94,067,951.74 | 304,285,693.55 | 242,081,764.07 |
| 利润总额 | 192,785,868.13 | 94,493,825.91 | 303,605,839.12 | 243,047,419.39 |
| 净利润 | 165,246,280.98 | 81,749,621.36 | 261,835,558.5 | 209,552,451.74 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | - | - |
| 综合收益总额 | 165,246,280.98 | 81,749,621.36 | 261,835,558.5 | 209,552,451.74 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 1,966,621,557.52 | 2,024,344,080.72 | 2,027,088,443.11 | 1,954,574,731.1 |
| 非流动资产: | | | | |
| 非流动资产合计 | 1,650,267,441.11 | 1,605,224,895.25 | 1,543,250,700.82 | 1,533,273,133.88 |
| 资产总计 | 3,616,888,998.63 | 3,629,568,975.97 | 3,570,339,143.93 | 3,487,847,864.98 |
| 流动负债: | | | | |
| 流动负债合计 | 362,177,219.12 | 365,172,511.27 | 394,787,415.44 | 373,926,334.86 |
| 非流动负债: | | | | |
| 非流动负债合计 | 24,067,685.07 | 27,087,863.31 | 26,338,947.97 | 19,578,132.87 |
| 负债合计 | 386,244,904.19 | 392,260,374.58 | 421,126,363.41 | 393,504,467.73 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 2,827,239,717.53 | 2,824,437,763.51 | 2,752,711,273.75 | 2,706,149,337.94 |
| 股东权益合计 | 3,230,644,094.44 | 3,237,308,601.39 | 3,149,212,780.52 | 3,094,343,397.25 |
| 负债和股东权益合计 | 3,616,888,998.63 | 3,629,568,975.97 | 3,570,339,143.93 | 3,487,847,864.98 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 715,552,704.25 | 346,181,076.3 | 1,503,172,363.21 | 1,125,494,646.11 |
| 经营活动现金流出小计 | 604,177,939.56 | 309,726,067.73 | 1,162,306,113.18 | 900,934,945.95 |
| 经营活动产生的现金流量净额 | 111,374,764.69 | 36,455,008.57 | 340,866,250.03 | 224,559,700.16 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 797,020,358.81 | 340,245,025.69 | 1,290,680,492.7 | 891,894,302.17 |
| 投资活动现金流出小计 | 796,001,480.22 | 380,067,747.1 | 1,760,273,490.93 | 1,368,390,490.67 |
| 投资活动产生的现金流量净额 | 1,018,878.59 | -39,822,721.41 | -469,592,998.23 | -476,496,188.5 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 18,728,358.8 | 3,154,780 | 62,147,566.47 | 56,916,336 |
| 筹资活动现金流出小计 | 98,353,067.36 | 401,568 | 95,860,226.7 | 95,611,548.59 |
| 筹资活动产生的现金流量净额 | -79,624,708.56 | 2,753,212 | -33,712,660.23 | -38,695,212.59 |
| 汇率变动对现金及现金等价物的影响 | -3,717,225.62 | -1,597,926.44 | -2,272,865.34 | -1,402,722.56 |
| 现金及现金等价物净增加额 | 29,051,709.1 | -2,212,427.28 | -164,712,273.77 | -292,034,423.49 |
| 期末现金及现金等价物余额 | 877,860,171.8 | 846,596,035.42 | 848,808,462.7 | 721,486,312.98 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 29,051,709.1 | - | -164,712,273.77 | - |